Lumito AB (publ) announced that The development of Lumito's first product (instrument + staining reagent) in digital tissue diagnostics, for analyzing tissue sections stained with the company's nano-based staining reagents, is entering its final stage prior to launch. The development of the actual instrument is proceeding according to plan, and the first instruments, which are intended for customer validation at reference clinics, are planned for delivery (with CE Mark approval) in April, Lumito's staining reagent development partner, RISE, has now announced that work on reagents still is on-going but is expected to be finished during the second quarter. This information is information that Lumito AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act.